表紙
市場調査レポート

Amura Holdings Ltd. - 製品パイプラインレビュー

Amura Holdings Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 253747
出版日 ページ情報 英文 22 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Amura Holdings Ltd. - 製品パイプラインレビュー Amura Holdings Ltd. - Product Pipeline Review - 2015
出版日: 2015年04月29日 ページ情報: 英文 22 Pages
概要

Amura Holdings Ltd.は英国に本社をおく創薬企業で、変形関節炎、骨粗鬆症、神経因性疼痛、自己免疫状態、転移性の骨疾患等に対する治療薬を設計、開発しています。同社はまた、細菌性の感染症治療に用いられるベータラクタマーゼ阻害剤(AM-112)に対する商標および知的財産権を有しています。

当レポートでは、Amura Holdings Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Amura Holdings Ltd.の基本情報

  • Amura Holdings Ltd.の概要
  • 主要情報
  • 企業情報

Amura Holdings Ltd.:R&Dの概要

  • 主な治療範囲

Amura Holdings Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Amura Holdings Ltd.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Amura Holdings Ltd.:薬剤プロファイル

  • AM-112
  • AM-3701
  • AM-3840
  • AM-3876
  • Small Molecules to Inhibit Cathepsin for Malaria

Amura Holdings Ltd.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Amura Holdings Ltd.:開発休止中のプロジェクト

Amura Holdings Ltd.:本社と子会社の所在地

  • 本社
  • 支社および子会社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07021CDB

Summary

Global Markets Direct's, 'Amura Holdings Ltd. - Product Pipeline Review - 2015', provides an overview of the Amura Holdings Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amura Holdings Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Amura Holdings Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Amura Holdings Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Amura Holdings Ltd.'s pipeline products

Reasons to buy

  • Evaluate Amura Holdings Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Amura Holdings Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Amura Holdings Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Amura Holdings Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amura Holdings Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Amura Holdings Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amura Holdings Ltd. Snapshot
    • Amura Holdings Ltd. Overview
    • Key Information
    • Key Facts
  • Amura Holdings Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Amura Holdings Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Amura Holdings Ltd. - Pipeline Products Glance
    • Amura Holdings Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Amura Holdings Ltd. - Drug Profiles
    • AM-112
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3701
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3840
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-3876
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Cathepsin for Malaria
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amura Holdings Ltd. - Pipeline Analysis
  • Amura Holdings Ltd. - Pipeline Products by Target
  • Amura Holdings Ltd. - Pipeline Products by Route of Administration
  • Amura Holdings Ltd. - Pipeline Products by Molecule Type
  • Amura Holdings Ltd. - Pipeline Products by Mechanism of Action
  • Amura Holdings Ltd. - Dormant Projects
  • Amura Holdings Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amura Holdings Ltd., Key Information
  • Amura Holdings Ltd., Key Facts
  • Amura Holdings Ltd. - Pipeline by Indication, 2015
  • Amura Holdings Ltd. - Pipeline by Stage of Development, 2015
  • Amura Holdings Ltd. - Monotherapy Products in Pipeline, 2015
  • Amura Holdings Ltd. - Preclinical, 2015
  • Amura Holdings Ltd. - Pipeline by Target, 2015
  • Amura Holdings Ltd. - Pipeline by Route of Administration, 2015
  • Amura Holdings Ltd. - Pipeline by Molecule Type, 2015
  • Amura Holdings Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Amura Holdings Ltd. - Dormant Developmental Projects,2015
  • Amura Holdings Ltd., Other Locations
  • Amura Holdings Ltd., Subsidiaries

List of Figures

  • Amura Holdings Ltd. - Pipeline by Top 10 Indication, 2015
  • Amura Holdings Ltd. - Pipeline by Top 10 Target, 2015
  • Amura Holdings Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Amura Holdings Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top